Pandemic Darlings The pandemic economy, in original documents
Home Source documents Senate Commerce Committee Statement to Senate, No. 1614 (March 14, 2022)

Senate Commerce Committee Statement to Senate, No. 1614 (March 14, 2022)

Summary

This is the Senate Commerce Committee Statement to Senate, No. 1614, State of New Jersey, dated March 14, 2022. The committee reports favorably Senate Bill No. 1614, which places a flat cap on out-of-pocket contributions for any covered person prescribed insulin, an epinephrine auto-injector device, or a prescription asthma inhaler. Coverage may not be subject to any deductible, and copayments or coinsurance are capped at $35 per 30-day supply of insulin, $25 per 30-day supply for epinephrine auto-injector devices, and $50 per 30-day supply for prescription asthma inhalers. The statement says the bill extends these standards to individual and small employer health benefits plans and is identical to Assembly Bill No. 2839 as reported by the committee.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“Senate Commerce Committee Statement to Senate, No. 1614 (March 14, 2022).” Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/2022-03-14-scm-s1614-s1-a158420c9e/, SHA-256 fa38a2e8606fd8b649ed399c31efc830f34f706941f92d1ef5b29baf4f510d2b.

Full text

     SENATE COMMERCE COMMITTEE

                   STATEMENT TO

                 SENATE, No. 1614

 STATE OF NEW JERSEY
                    DATED: MARCH 14, 2022

   The Senate Commerce Committee reports favorably Senate Bill
No. 1614.
   This bill places a flat cap on the out-of-pocket contribution for
any covered person prescribed insulin, an epinephrine auto-injector
device, or a prescription asthma inhaler across insurance providers.
Coverage for these items may not be subject to any deductible, and
copayments or coinsurance are capped at $35 per 30-day supply of
insulin, $25 for epinephrine auto-injector devices per 30-day
supply, and $50 for prescription asthma inhalers per 30-day supply.
   These coverage standards apply to individual or group hospital
service corporations, medical service corporations, and health
service corporations as well as individual and group health
insurance policies and health maintenance organizations.
Additionally, the bill extends these coverage standards to individual
and small employer health benefits plans and require that the State
Health Benefits Commission and the School Employee’s Health
Benefits Commission ensure that their contracts comply with the
coverage standards.
    As reported by the committee, this bill is identical to Assembly
Bill No. 2839.

File and source

File
2022-03-14_SCM_S1614_S1.pdf
Size
112,466 bytes
SHA-256
fa38a2e8606fd8b649ed399c31efc830f34f706941f92d1ef5b29baf4f510d2b
Our copy
2022-03-14_SCM_S1614_S1.pdf
Original
No public link identified.
Back to top